Blog
RSS FeedPosted by Michael Wonder on 20 Jun 2024
Truqap plus Faslodex approved in the EU for patients with advanced oestrogen receptor positive breast cancer
20 June 2024 - Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or ...
Posted by Michael Wonder on 20 Jun 2024
Golidocitinib approved in China as first in class JAK1 only inhibitor for the treatment of relapsed or refractory peripheral T-cell lymphoma
19 June 2024 - Golidocitinib is a first-in-class Janus kinase 1 only inhibitor approved for the treatment of relapsed/refractory PTCL based ...
Posted by Michael Wonder on 20 Jun 2024
KalVista submits new drug application to FDA for sebetralstat as first oral on-demand treatment for hereditary angioedema
18 June 2024 - KalVista Pharmaceuticals today announced the submission of a new drug application for US FDA review of ...
Posted by Michael Wonder on 19 Jun 2024
National cancer drug promise: PHARMAC Minister won’t guarantee those 13 drugs will be funded
19 June 2024 - The minister responsible for New Zealand’s drugbuying agency PHARMAC is at odds with the Minister of ...
Posted by Michael Wonder on 19 Jun 2024
Tafamidis meglumine for the treatment of patients with transthyretin amyloidosis with cardiomyopathy (final guidance)
19 June 2024 - NICE has published final evidence-based recommendations on the use of tafamidis meglumine (Vyndaqel) for the treatment ...
Posted by Michael Wonder on 19 Jun 2024
US FDA approves Skyrizi (risankizumab-rzaa) for ulcerative colitis, expanding AbbVie's portfolio across inflammatory bowel disease
18 June 2024 - Approval supported by two Phase 3 clinical trials that evaluated Skyrizi for the treatment of moderate to ...
Posted by Michael Wonder on 18 Jun 2024
PHARMAC improves access to breast cancer treatments
18 June 2024 - PHARMAC has changed the criteria for two breast cancer medicines which means people with a particular ...
Posted by Michael Wonder on 18 Jun 2024
US FDA rare paediatric disease designation granted to RC220 bisantrene for the treatment of paediatric AML
18 June 2024 - Race Oncology is pleased to announce that the US FDA has extended rare paediatric disease designation ...
Posted by Michael Wonder on 18 Jun 2024
Subcutaneous amivantamab biologics license application submitted to US FDA for patients with EGFR mutated non-small-cell lung cancer
17 June 2024 - Application based on Phase 3 PALOMA-3 results showing five-fold reduction in infusion-related reactions with five minute administration ...
Posted by Michael Wonder on 18 Jun 2024
Awiqli - world's first once-weekly basal insulin - now available in Canada
17 June 2024 - Novo Nordisk is pleased to announce Canada will be the first country worldwide to launch Awiqli (insulin ...
Posted by Michael Wonder on 17 Jun 2024
FDA approves pembrolizumab with chemotherapy for primary advanced or recurrent endometrial carcinoma
17 June 2024 - Today, the FDA approved pembrolizumab (Keytruda, Merck) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for ...
Posted by Michael Wonder on 16 Jun 2024
First new Alzheimer’s drugs in 20 years to bring hope for early stage patients
16 June 2024 - Two new Alzheimer’s drugs aimed at slowing cognitive delay and heralded as a step towards prevention ...
Posted by Michael Wonder on 15 Jun 2024
Extremely rare disease drug Ceprotin clears major hurdle to reimbursement
14 June 2024 - Ceprotin (protein C concentrate), an ultra-rare disease treatment developed by Takeda Pharmaceutical Korea, has passed the ...
Posted by Michael Wonder on 15 Jun 2024
Blue Cross Blue Shield of Michigan dropping coverage of weight loss drugs
14 June 2024 - Michigan's largest insurance company said it will begin eliminating coverage of various weight loss drugs next ...
Posted by Michael Wonder on 14 Jun 2024
FDA approves blinatumomab as consolidation for CD19 positive Philadelphia chromosome negative B-cell precursor acute lymphoblastic leukaemia
14 June 2024 - Today, the FDA approved blinatumomab (Blincyto, Amgen) for adult and paediatric patients one month and older ...